TESI DOTTORATO MICAELA RANIERI - DSpace - Tor Vergata

93. Farrell R, Alsahli M, Falchuk K, Peppercorn M, Michetti P Human antichimeric
antibody levels correlate with lack of response and infusion reactions
following infliximab therapy. Gastroenterology 2002; 120: A-69.
94. Sandborn William J., Faegan B.G., Stoinov S., Pieter J., Honiball,
Rutgeerts P., Mason D., Bloomfield R., Schreiber S. Certolizumab Pegol for
the Treatment of Crohn’s Disease. N Engl J Med 2007; 357: 228-38.
95. Schreiber S., Khaliq-Kareemi M., Lawrence I.C., Thomsen O., Hanauer
S.B., McColm J., Bloomfield R., Sandborn W. Maintenance Therapy with
Certolizumab Pegol for Crohn’s Disease. N Engl J Med 2007; 357: 239-50.
96. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M.,
Macintosh D., Panaccione R., Wolf D., Pollack P. Human Anti-Tumor
Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the
CLASSIC-I Trial. Gastroenterology 2006; 130: 323-333.
97. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B.,
Panaccione R., Schreiber S., Byczkowski D., Ju Li, Kent J.D., Pollack P.
Adalimumab for Maintenance of Clinical Response and Remission in Patients
With Crohn’s Disease: The CHARM Trial. Gastroenterology 2007; 132: 52-
65.
98. Joel R. Rosh, MD, Thomas Gross, MD, Petar Mamula, MD, Anne
Griffiths, MD, and Jeffrey Hyams,Hepatosplenic T-cell Lymphoma in
Adolescents and Young Adults with Crohn’s Disease: A Cautionary Tale?
Inflamm Bowel Dis Volume 13, Number 8, August 2007
99. Ann Corken Mackey, Lanh Green, Li-ching Liang,Patricia Dinndorf, and
Mark Avigan
Hepatosplenic T Cell Lymphoma Associated With Infliximab Use in Young
Patients Treated forInflammatory Bowel Disease. J Pediatr Gastroenterol
Nutr, Vol. 44, No. 2, February 2007
100 P L Travis, E F Stange, M Le´mann, T O¨ resland, Y Chowers, A Forbes,
G D’Haens, G Kitis,A Cortot, C Prantera, P Marteau, J-F Colombel, P
Gionchetti, Y Bouhnik, E Tiret, J Kroesen,M Starlinger, N J Mortensen, for the
European Crohn’s and Colitis Organisation (ECCO)
European evidence based consensus on the diagnosis and management of
Crohn’s disease: current management.Gut 2006 55: i16-i35
101 B Hanauer, Brian G Feagan, Gary R Lichtenstein, Lloyd F Mayer, S
Schreiber, Jean Frederic Colombel,Daniel Rachmilewitz, Douglas C Wolf,
Allan Olson, Weihang Bao, Paul Rutgeerts, and the ACCENT I Study Group
Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial.
The Lancet Vol 359 • May 4, 2002
102 A. Siegel,Sadie M. Marden, Sarah M. Persing, Robin J. Larson,and Bruce
E. Sands.Risk of Lymphoma Associated With Combination Anti–Tumor
82